Publications
Detailed Information
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study : Amivantamab in egfr exon 20 insertion- mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the chrysalis phase i study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Keunchil | - |
dc.contributor.author | Haura, Eric B. | - |
dc.contributor.author | Leighl, Natasha B. | - |
dc.contributor.author | Mitchell, Paul | - |
dc.contributor.author | Shu, Catherine A. | - |
dc.contributor.author | Girard, Nicolas | - |
dc.contributor.author | Viteri, Santiago | - |
dc.contributor.author | Han, Ji-Youn | - |
dc.contributor.author | Kim, Sang-We | - |
dc.contributor.author | Lee, Chee Khoon | - |
dc.contributor.author | Sabari, Joshua K. | - |
dc.contributor.author | Spira, Alexander, I | - |
dc.contributor.author | Yang, Tsung-Ying | - |
dc.contributor.author | Kim, Dong Wan | - |
dc.contributor.author | Lee, Ki Hyeong | - |
dc.contributor.author | Sanborn, Rachel E. | - |
dc.contributor.author | Trigo, Jose | - |
dc.contributor.author | Goto, Koichi | - |
dc.contributor.author | Lee, Jong Seok | - |
dc.contributor.author | Yang, James Chih-Hsin | - |
dc.contributor.author | Govindan, Ramaswamy | - |
dc.contributor.author | Bauml, Joshua M. | - |
dc.contributor.author | Garrido, Pilar | - |
dc.contributor.author | Krebs, Matthew G. | - |
dc.contributor.author | Reckamp, Karen L. | - |
dc.contributor.author | Xie, John | - |
dc.contributor.author | Curtin, Joshua C. | - |
dc.contributor.author | Haddish-Berhane, Nahor | - |
dc.contributor.author | Roshak, Amy | - |
dc.contributor.author | Millington, Dawn | - |
dc.contributor.author | Lorenzini, Patricia | - |
dc.contributor.author | Thayu, Meena | - |
dc.contributor.author | Knoblauch, Roland E. | - |
dc.contributor.author | Cho, Byoung Chul | - |
dc.date.accessioned | 2023-03-20T08:50:34Z | - |
dc.date.available | 2023-03-20T08:50:34Z | - |
dc.date.created | 2022-03-11 | - |
dc.date.created | 2022-03-11 | - |
dc.date.created | 2022-03-11 | - |
dc.date.issued | 2021-10 | - |
dc.identifier.citation | Journal of Clinical Oncology, Vol.39 No.30, pp.3391-3402 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://hdl.handle.net/10371/189538 | - |
dc.description.abstract | PURPOSE Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody with immune cell-directing activity, binds to each receptor's extracellular domain, bypassing resistance at the tyrosine kinase inhibitor binding site. METHODS CHRYSALIS is a phase I, open-label, dose-escalation, and dose-expansion study, which included a population with EGFR Exon20ins NSCLC. The primary end points were dose-limiting toxicity and overall response rate. We report findings from the postplatinum EGFR Exon20ins NSCLC population treated at the recommended phase II dose of 1,050 mg amivantamab (1,400 mg, >= 80 kg) given once weekly for the first 4 weeks and then once every 2 weeks starting at week 5. RESULTS In the efficacy population (n = 81), the median age was 62 years (range, 42-84 years); 40 patients (49%) were Asian, and the median number of previous lines of therapy was two (range, 1-7). The overall response rate was 40% (95% CI, 29 to 51), including three complete responses, with a median duration of response of 11.1 months (95% CI, 6.9 to not reached). The median progression-free survival was 8.3 months (95% CI, 6.5 to 10.9). In the safety population (n = 114), the most common adverse events were rash in 98 patients (86%), infusion-related reactions in 75 (66%), and paronychia in 51 (45%). The most common grade 3-4 adverse events were hypokalemia in six patients (5%) and rash, pulmonary embolism, diarrhea, and neutropenia in four (4%) each. Treatment-related dose reductions and discontinuations were reported in 13% and 4% of patients, respectively. CONCLUSION Arnivantamab, via its novel mechanism of action, yielded robust and durable responses with tolerable safety in patients with EGFR Exon20ins mutations after progression on platinum-based chemotherapy. (C) 2021 by American Society of Clinical Oncology | - |
dc.language | 영어 | - |
dc.publisher | American Society of Clinical Oncology | - |
dc.title | Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study | - |
dc.title.alternative | Amivantamab in egfr exon 20 insertion- mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the chrysalis phase i study | - |
dc.type | Article | - |
dc.identifier.doi | 10.1200/JCO.21.00662 | - |
dc.citation.journaltitle | Journal of Clinical Oncology | - |
dc.identifier.wosid | 000753373000009 | - |
dc.identifier.scopusid | 2-s2.0-85112311967 | - |
dc.citation.endpage | 3402 | - |
dc.citation.number | 30 | - |
dc.citation.startpage | 3391 | - |
dc.citation.volume | 39 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Dong Wan | - |
dc.contributor.affiliatedAuthor | Lee, Jong Seok | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | GROWTH-FACTOR RECEPTOR | - |
dc.subject.keywordPlus | BISPECIFIC ANTIBODY | - |
dc.subject.keywordPlus | GENE-MUTATIONS | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | JNJ-61186372 | - |
dc.subject.keywordPlus | GEFITINIB | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | NSCLC | - |
dc.subject.keywordPlus | CMET | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.